BioSpace News Archive

Aligos Therapeutics, Inc., a private biotechnology company focused on the development of targeted, antiviral therapies including chronic hepatitis B (CHB) and COVID-19 as well as therapeutics for NASH, today announced that Lawrence Blatt, Ph.D., MBA , Chief Executive Officer of Aligos, will present at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 1:30 p.m. Eastern Time.

In a joint statement, emergency medicine and other leading medical associations, academics and psychiatry experts outline steps to support the mental health of emergency physicians and other health professionals currently risking their lives to treat patients during this pandemic.

With America on lockdown the past two months, many people turned to the woods for safe isolation and social distancing.

Food Allergy Research & Education continues innovation through accelerated therapy, diagnostics and prevention strategies

LaunchPad Medical, Inc. announced that it has received follow-on support of up to $1.8 million from the Michigan-Pittsburgh-Wyss Regenerative Medicine Resource Center which was funded by the National Institute of Dental and Cranial Research (U24-DE029462) to improve the translation of promising tissue engineering and regenerative medicine technologies for dental, oral, and craniofacial clinical practice.

ELITechGroup, recognized worldwide for proven performance and reliability of clinical laboratory instruments is pleased to announce the release of FreezePoint™ Freezing Point Osmometer.

CalciMedica Inc. announced the appointment of Robert N. Wilson, a former vice chairman of the Johnson & Johnson board, to the Company’s board of directors as co-chairman with current board chairman, Robert McNeil, Ph.D.

Anika Therapeutics, Inc. announced that Sylvia Cheung, Chief Financial Officer, has informed the Board of Directors of her decision, following a period of transition, to step away from her role at Anika effective August 21, 2020.

Protara Therapeutics, Inc. (Nasdaq: TARA), a development-stage clinical biopharmaceutical company developing treatments for rare and specialty diseases with significant unmet needs, today announced the grants of inducement non-qualified stock options to purchase an aggregate of 3,700 shares of common stock to one new employee.

Iovance Biotherapeutics, Inc. (Nasdaq:IOVA) (“Iovance” or “Company”), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today announced the closing of an underwritten public offering of 19,475,806 shares of its common stock at a public offering price of $31.00 per share.